# The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor

Study · id `cardio:ct-nct03400267` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03400267](<https://clinicaltrials.gov/study/NCT03400267>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03400267

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT03400267. Randomized; no masking; primary purpose treatment. Start 2018-02-16 (actual); primary completion 2019-10-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT03400267, source copy `cardio:ctgov-nct03400267-2020-02-12`, retrieved 2026-10-26)
- Started: 2018-02-16 (actual) (ClinicalTrials.gov record NCT03400267, source copy `cardio:ctgov-nct03400267-2020-02-12`, retrieved 2026-10-26)
- Primary completion: 2019-10-22 (actual) (ClinicalTrials.gov record NCT03400267, source copy `cardio:ctgov-nct03400267-2020-02-12`, retrieved 2026-10-26)
- Completion: 2019-11-22 (actual) (ClinicalTrials.gov record NCT03400267, source copy `cardio:ctgov-nct03400267-2020-02-12`, retrieved 2026-10-26)
- Countries: Netherlands (ClinicalTrials.gov record NCT03400267, source copy `cardio:ctgov-nct03400267-2020-02-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03400267-2020-02-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor
- Acronym: ON-TIME 3
- Condition: STEMI
- Condition: STEMI - ST Elevation Myocardial Infarction
- Intervention (Drug): Paracetamol
- Intervention (Drug): Fentanyl
- Lead sponsor: A.H. Tavenier
- Lead sponsor class: OTHER
- Collaborator: Isala
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as a collaborator: Isala (`cardio:org-isala`)

## Provenance

Content hash: 72b7b8fc42a0979b4c4849df4cdc39e7c5496d958f25b76516763d3e26616f37
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
